Table 2.
Dosing table used in studies 1305, 008 and 009. Doses specified are in mg
| Baseline IgE | Body weight (kg) | |||||
|---|---|---|---|---|---|---|
| IU ml−1 | ng ml−1 | 30–60 | >60–70 | >70–80 | >80–90 | >90–150 |
| ≥30–100 | ≥72.6–242 | 150 | 150 | 150 | 150 | 300 |
| >100–200 | >242–484 | 300 | 300 | 300 | 300 | 225 |
| >200–300 | >484–726 | 300 | 225 | 225 | 225 | 300 |
| >300–400 | >726–968 | 225 | 225 | 300 | 300 | – |
| >400–500 | >968–1210 | 300 | 300 | 375 | 375 | – |
| >500–600 | >1210–1452 | 300 | 375 | – | – | – |
| >600–700 | >1452–1694 | 375 | – | – | – | – |
*Omalizumab dose administered by subcutaneous injection every 2 weeks (in bold) or 4 weeks (not bold).